STUDIES IN AUTOLOGOUS BONE MARROW TRANSPLANTATION

自体骨髓移植的研究

• 批准号: 3093024
• 负责人: KAREL A DICKE
• 金额: $ 58.06万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 1979
• 资助国家: 美国
• 起止时间: 1979-01-01 至 1987-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3093024
• 关键词: autologous transplantation; bone marrow transplantation; neoplasm /cancer therapy

The major clincal objective is to study whether removal of leukemic cells from the autologous bone marrow graft has biological significance in vivo. This is studied in acute leukemia patients who are in second and subsequent remission, pretreated with a high dose combination chemotherapy regimen: CBV (Cytoxan, 6 gr M2; BCNU, 300 mmg/M2, and VP-16. 600 mg/M2 We plan to continue our clinical autologous bone marrow transplantation studies in second and subsequent remission patients. We will continue to study the hemopoietic restoration potential in vivo of hemopoietic precursor concentrates obtained by percoll density gradient centrifugation of marrow cell suspensions. The preparation of such concentrates is necessary to avoid clumping of the cells at time of immunocolloidal separation. At the end of the coming year we expect to have solid information concerning the in vivo hemopoietic restoration capability of such concentrates. Hopefully, we will already have initiated clinical studies at that time with purged marrow cell suspensions using the improved, modified immunoseparation procedure.

主要临床目的是研究白血病细胞的去除是否 具有生物学意义。 这项研究是在急性白血病患者谁是在第二次和以后 缓解，接受高剂量联合化疗方案预治疗： CBV（环磷酰胺，6 gr M2; BCNU，300 mmg/M2和VP-16。 600 mg/M2 我们计划继续临床自体骨髓移植 在第二次和随后的缓解患者中进行的研究。 我们将继续 研究造血干细胞在体内的造血恢复潜力， 通过离心密度梯度离心获得的前体浓缩物 骨髓细胞悬液。 这种浓缩物的制备是 在免疫胶体时避免细胞聚集是必要的 分居 在明年年底，我们预计将有坚实的 关于体内造血恢复能力的信息 这样的浓缩物。 希望我们已经开始了临床试验 当时的研究使用净化的骨髓细胞悬液， 改良的免疫分离方法。